Genmab AS Stock Performance
| GMAB Stock | USD 26.45 0.31 1.19% |
The company has a beta of 1.16, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Genmab AS will likely underperform. At this point, Genmab AS has a negative expected return of -0.25%. Please make sure to check Genmab AS's skewness, accumulation distribution, and the relationship between the value at risk and rate of daily change, to decide if Genmab AS's performance from the past will be repeated at some future point.
Risk-Adjusted Performance
Weak
Weak | Strong |
Genmab AS has delivered negative risk-adjusted returns across the last 90 days, suggesting that volatility was not compensated by return. Current market capitalization is about 16.07 Billion. Despite conflicting performance in the last few months, the stock's basic indicators remain somewhat strong, which may send shares a bit higher in April 2026. The current disturbance may also be a sign of long term up-swing for the company's investors. Learn More
Actual Historical Performance (%)
One Day Return -1.62 | Five Day Return -1.54 | Year To Date Return -17.85 | Ten Year Return 112 | All Time Return 593.37 |
Last Split Factor 5:1 | Last Split Date 2018-05-01 |
1 | Genmab shelves Phase III lung cancer candidate | 12/30/2025 |
2 | CD 137 Targeted Therapy Research Report 2026-2030 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global Regional Clinical Commercial Trends, | 01/23/2026 |
3 | H.C. Wainwright Bullish on Genmab AS on Robust Sales for DARZALEX | 02/13/2026 |
4 | A Glimpse Into The Expert Outlook On Genmab Through 4 Analysts | 02/17/2026 |
5 | Genmab AS Releases Quarterly Earnings Results, Misses Estimates By 0.41 EPS | 02/18/2026 |
6 | Transactions with shares and linked securities in Genmab AS made by managerial employees and their closely associated persons | 02/20/2026 |
7 | Genmab to Participate in Upcoming Investor Conferences | 02/25/2026 |
8 | Russell Investments Group Ltd. Has 25.23 Million Holdings in Genmab AS Sponsored ADR GMAB | 03/13/2026 |
| Begin Period Cash Flow | 8.7 B | |
| Total Cashflows From Investing Activities | -36 B |
Relative Risk vs. Return Landscape
If you had invested $ 3,135 in Genmab AS on December 16, 2025 and sold it today you would have lost $ 490.00 from holding Genmab AS or given up 15.63% of portfolio value over 90 days. Genmab AS does not currently generate positive expected returns and carries 2.3426% risk (volatility on return distribution) over a 90-day horizon. In different words, 21% of stocks are less volatile than Genmab, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
The tendency of Genmab Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of organized markets for forecasting. However, many studies suggest that some traded stocks are consistently mispriced before demand and supply correct the spread. One possible explanation is that these stocks carry additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 26.45 | 90 days | 26.45 | about 98.0 |
Based on a normal probability distribution, the odds of Genmab AS moving above the current price in 90 days from now are about 98.0 (This Genmab AS probability density function shows the probability of Genmab Stock falling within a particular range of prices over 90 days).
Genmab AS Price Density |
| Price |
Predictive Modules for Genmab AS
There are currently many different techniques concerning forecasting the stock market as a whole, as well as predicting future values of individual instruments such as Genmab AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Genmab AS's price to converge to an average value over time is called mean reversion.
Primary Risk Indicators
The last 10-20 years have been a volatile period for the stock market. Genmab AS is no exception. The market experienced several large corrections towards Genmab AS's value, including sharp drops and substantial rallies. An investor can limit portfolio swings by implementing a hedging strategy designed to reduce downside losses. If you hold Genmab AS, one way to protect your portfolio is to watch for changing volatility and market elasticity of Genmab AS within the framework of fundamental risk indicators.α | Alpha over Dow Jones | -0.2335 | |
β | Beta against Dow Jones | 1.16 | |
σ | Overall volatility | 2.22 | |
Ir | Information ratio | -0.1015 |
Investor Alerts and Insights
Automated alerts tied to Genmab AS help investors stay ahead of material changes in stock conditions. Monitoring ongoing notifications for Genmab AS is a practical way to spot shifts in technical or fundamental signals that may affect investment timing.| Genmab AS generated a negative expected return over the last 90 days | |
| Latest headline from thelincolnianonline.com: Russell Investments Group Ltd. Has 25.23 Million Holdings in Genmab AS Sponsored ADR GMAB |
Price Density Drivers
Market volatility typically increases when nervous long traders begin to feel pressure from short-sellers driving the market lower. The future price of Genmab Stock often depends not only on the outlook of current and potential investors but also on the ongoing dynamics between traders with different styles. Genmab AS's indicators related to short sentiment are summarized below.
| Common Stock Shares Outstanding | 626.9 M | |
| Cash And Short Term Investments | 10.9 B |
Genmab AS Fundamentals Growth
Genmab Stock prices reflect investors' perceptions of the future prospects and financial health of Genmab AS, and Genmab AS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Stock performance.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.081 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 19.85 B | |||
| Shares Outstanding | 614.87 M | |||
| Price To Earning | 66.53 X | |||
| Price To Book | 2.75 X | |||
| Price To Sales | 4.32 X | |||
| Revenue | 23.73 B | |||
| Gross Profit | 3.48 B | |||
| EBITDA | 8.43 B | |||
| Net Income | 6.14 B | |||
| Cash And Equivalents | 21.61 B | |||
| Cash Per Share | 33.05 X | |||
| Total Debt | 35.36 B | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 13.11 X | |||
| Book Value Per Share | 94.89 X | |||
| Cash Flow From Operations | 7.56 B | |||
| Earnings Per Share | 1.54 X | |||
| Market Capitalization | 16.07 B | |||
| Total Asset | 81.86 B | |||
| Retained Earnings | 26.06 B | |||
| Working Capital | 1.46 B | |||
| Current Asset | 12.65 B | |||
| Current Liabilities | 823.51 M | |||
Performance Metrics & Calculation Methodology
Genmab AS performance is measured on a risk-adjusted basis against benchmarks. Risk-adjusted measures provide context for return efficiency across regimes. Genmab AS shows ROE of 17.54%, ROA of 8.1%.
Unless otherwise specified, data for Genmab AS is compiled from periodic company reporting and market reference feeds and standardized for comparability. Where analyst coverage exists, consensus estimates are factored in. Updates may occur throughout the day. Return and risk statistics are calculated from historical price series.